Search

Your search keyword '"Rifkin R"' showing total 210 results
Start Over Author "Rifkin R"
210 results on '"Rifkin R"'

3. P947: COMPARATIVE EFFECTIVENESS OF ORAL IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE (IRD) AFTER INITIAL BORTEZOMIB (V)-BASED INDUCTION VS PARENTERAL V-BASED THERAPY IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

Author

Rifkin, R. M., primary, Costello, C. L., additional, Birhiray, R. E., additional, Kambhampati, S., additional, Richter, J., additional, Abonour, R., additional, Lee, H. C., additional, Kim, Y. J., additional, Ren, K., additional, Stull, D. M., additional, Cherepanov, D., additional, Bogard, K., additional, Noga, S. J., additional, and Girnius, S., additional

Published
2022
Full Text
View/download PDF

4. PB2012: A PHASE 2 MULTIARM STUDY OF MAGROLIMAB COMBINATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

Author

Paul, B., primary, Liedtke, M., additional, Siegel, D. S., additional, Khouri, J., additional, Hillenglass, J., additional, Rifkin, R., additional, Gandhi, M. D., additional, Kin, A., additional, Levy, M. Y., additional, Mohrbacher, A., additional, Schmidt, W., additional, Silbermann, R., additional, Cottini, F., additional, Sborov, D. W., additional, Walker, R., additional, Murphy, M., additional, Gu, L., additional, Chen, A., additional, Rajakumaraswamy, N., additional, and Usmani, S. Z., additional

Published
2022
Full Text
View/download PDF

5. B

Author

Poggio, T., Mukherjee, S., Rifkin, R., Raklin, A., Verri, A., Winkler, Joab, editor, and Niranjan, Mahesan, editor

Published
2002
Full Text
View/download PDF

7. P13: CAN PATIENT-REPORTED OCULAR SYMPTOMS GUIDE DOSE MODIFICATIONS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING BELANTAMAB MAFODOTIN?

Author

Popat, R, primary, Badros, A, additional, Kumar, S, additional, Rodriguez-Otero, P, additional, Cohen, A, additional, Manier, S, additional, Voorhees, P, additional, Gay, F, additional, Rifkin, R, additional, Martin, T, additional, Chari, A, additional, Weisel, K, additional, Farooq, A, additional, Jeng, B, additional, Chng, W, additional, Lee, H, additional, Berdeja, J, additional, Jadhav, V, additional, Tosolini, A, additional, Eliason, L, additional, Palumbo, A, additional, Dimopoulos, M, additional, Lonial, S, additional, Trudel, S, additional, Richardson, P, additional, and Terpos, E, additional

Published
2022
Full Text
View/download PDF

9. 53P Incidence of febrile neutropenia (FN), adherence and compliance to granulocyte colony-stimulating factor (G-CSF) on-body injector (OBI) versus other FN prophylaxis in patients receiving myelosuppressive chemotherapy: Subgroup analysis in breast cancer patients

Author

Mahtani, R., primary, Lyman, G.H., additional, Rifkin, R., additional, Dale, D., additional, Brookhart, A., additional, Lewis, S., additional, Decosta, L., additional, Lawrence, T., additional, Belani, R., additional, and Crawford, J., additional

Published
2021
Full Text
View/download PDF

11. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.

Author

Usmani S.Z., Oriol A., Karlin L., Cavo M., Rifkin R.M., Hayek F., Kirschner E., Bharany N., Overton L., Mannem S., Harroff A., Jain S., Roque T., McIntyre K., Yasencha C.K., Houck W., Schjesvold F., Yimer H.A., LeBlanc R., Takezako N., McCroskey R.D., Lim A.B.M., Suzuki K., Kosugi H., Grigoriadis G., Avivi I., Facon T., Jagannath S., Lonial S., Ghori R.U., Farooqui M.Z.H., Marinello P., San-Miguel J., Lim A., Walker T., Nicol A., Reece D., Elemary M., Boudreault Pedneault J.S., Attal M., Weisel K., Engelhardt M., Mackensen A., Quinn J., Cohen A., Magen-Nativ H., Benyamini N., Larocca A., Matsumoto M., Iida S., Ishikawa T., Kondo Y., Sunami K., Ando K., Teshima T., Chou T., Iwasaki H., Miki H., Matsumura I., Onishi Y., Izutsu K., Kizaki M., George A., Blacklock H., Simpson D., Waage A., Samoilova O., Nikitin E., Chagorova T., McDonald A., Patel M., Oriol Rocafiguera A., San Miguel Izquierdo J., Mateos M., Streetly M., Forsyth P., Jackson G., Jenkins S., Rifkin R., Yimer H., McCroskey R., Martincic D., Tarantolo S., Larson S., Faroun Y., Vaughn J., Baz R., Saylors G., Neppalli A., Raptis A., Fung H., Janosky M., Stevens D., Coleman M., Costa D., Cross S., Fanning S., Berges D.F., Harris T., Zackon I., Atanackovic D., Lee K., Oliff I., Lee W., Bensinger W., Lutzky J., Baron A., Usmani S.Z., Oriol A., Karlin L., Cavo M., Rifkin R.M., Hayek F., Kirschner E., Bharany N., Overton L., Mannem S., Harroff A., Jain S., Roque T., McIntyre K., Yasencha C.K., Houck W., Schjesvold F., Yimer H.A., LeBlanc R., Takezako N., McCroskey R.D., Lim A.B.M., Suzuki K., Kosugi H., Grigoriadis G., Avivi I., Facon T., Jagannath S., Lonial S., Ghori R.U., Farooqui M.Z.H., Marinello P., San-Miguel J., Lim A., Walker T., Nicol A., Reece D., Elemary M., Boudreault Pedneault J.S., Attal M., Weisel K., Engelhardt M., Mackensen A., Quinn J., Cohen A., Magen-Nativ H., Benyamini N., Larocca A., Matsumoto M., Iida S., Ishikawa T., Kondo Y., Sunami K., Ando K., Teshima T., Chou T., Iwasaki H., Miki H., Matsumura I., Onishi Y., Izutsu K., Kizaki M., George A., Blacklock H., Simpson D., Waage A., Samoilova O., Nikitin E., Chagorova T., McDonald A., Patel M., Oriol Rocafiguera A., San Miguel Izquierdo J., Mateos M., Streetly M., Forsyth P., Jackson G., Jenkins S., Rifkin R., Yimer H., McCroskey R., Martincic D., Tarantolo S., Larson S., Faroun Y., Vaughn J., Baz R., Saylors G., Neppalli A., Raptis A., Fung H., Janosky M., Stevens D., Coleman M., Costa D., Cross S., Fanning S., Berges D.F., Harris T., Zackon I., Atanackovic D., Lee K., Oliff I., Lee W., Bensinger W., Lutzky J., and Baron A.

Abstract

Background: Lenalidomide and dexamethasone has been a standard of care in transplant-ineligible patients with newly diagnosed multiple myeloma. The addition of a third drug to the combination is likely to improve treatment efficacy. KEYNOTE-185 assessed the efficacy and safety of lenalidomide and dexamethasone with and without pembrolizumab in patients with previously untreated multiple myeloma. Here, we present the results of an unplanned interim analysis done to assess the benefit-risk of the combination at the request of the US Food and Drug Administration (FDA). Method(s): KEYNOTE-185 was a randomised, open-label, phase 3 trial done at 95 medical centres across 15 countries (Australia, Canada, France, Germany, Ireland, Israel, Italy, Japan, New Zealand, Norway, Russia, South Africa, Spain, UK, and USA). Transplantation-ineligible patients aged 18 years and older with newly diagnosed multiple myeloma, Eastern Cooperative Oncology Group performance status of 0 or 1, and who were treatment naive were enrolled, and randomly assigned 1:1 to receive either pembrolizumab plus lenalidomide and dexamethasone or lenalidomide and dexamethasone alone using an interactive voice or integrated web response system. Patients received oral lenalidomide 25 mg on days 1-21 and oral dexamethasone 40 mg on days 1, 8, 15, and 22 of repeated 28-day cycles, with or without intravenous pembrolizumab 200 mg every 3 weeks. The primary endpoint was progression-free survival, which was investigator-assessed because of early trial termination. Efficacy was analysed in all randomly assigned patients and safety was analysed in all patients who received at least one dose of study drug. This trial is registered at ClinicalTrials.gov, number NCT02579863, and it is closed for accrual. Finding(s): Between Jan 7, 2016, and June 9, 2017, 301 patients were randomly assigned to the pembrolizumab plus lenalidomide and dexamethasone group (n=151) or the lenalidomide and dexamethasone group (n=150). On Jul

Published
2019

12. Analysis of CFAR performance in Weibull clutter

Author

Rifkin, R.

Subjects
Algorithms -- Analysis, Signal detection (Electronics) -- Research, Radar systems -- Interference, Electromagnetic interference -- Research, Weibull distribution -- Usage, Aerospace and defense industries, Business, Computers, Electronics, Electronics and electrical industries
Abstract

Recent interest has focused on order statistic-based (OS-based) algorithms for calculating radar detection thresholds. Previous analyses of these algorithms are extended, to determine closed-form approximations for the signal-to-clutter ratio required to achieve a particular probability of detection in clutter environments whose amplitude statistics are modeled by the Weibull distribution, and where the clutter dominates receiver noise. Performance is evaluated in both homogeneous and inhomogenous clutter. The analysis shows that the OS-based algorithm is quite robust against both interference and clutter edges. A method is suggested for improving performance at clutter inhomogeneities for short-range targets.

Published
1994

13. PS1419 COMPARATIVE EFFECTIVENESS OF TRIPLETS CONTAINING BORTEZOMIB (B), CARFILZOMIB (C), DARATUMUMAB (D), OR IXAZOMIB (I) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) IN ROUTINE CARE IN THE US

Author

Davies, F., primary, Rifkin, R., additional, Costello, C., additional, Usmani, S., additional, Abonour, R., additional, Palumbo, A., additional, Romanus, D., additional, Hajek, R., additional, Terpos, E., additional, Stull, D.M., additional, Huang, H., additional, Leleu, X., additional, Berdeja, J., additional, Lee, H., additional, Weisel, K., additional, Thompson, M., additional, Boccadoro, M., additional, Zonder, J., additional, Cook, G., additional, Puig, N., additional, Vela-Ojeda, J., additional, Skacel, T., additional, Farrelly, E., additional, Raju, A., additional, Blazer, M., additional, and Chari, A., additional

Published
2019
Full Text
View/download PDF

14. PF601 EVOLVING TREATMENT PATTERNS IN MULTIPLE MYELOMA (MM) DIFFER BY AGE AND REGION: ANALYSIS FROM INSIGHT MM, A GLOBAL, PROSPECTIVE, OBSERVATIONAL STUDY

Author

Chari, A., primary, Weisel, K.C., additional, Usmani, S.Z., additional, Davies, F.E., additional, van Rhee, F., additional, Rifkin, R., additional, Zonder, J.A., additional, Costello, C., additional, Thompson, M.A., additional, Berdeja, J., additional, Lee, H.C., additional, Abonour, R., additional, Omel, J., additional, Hajek, R., additional, Spencer, A., additional, Terpos, E., additional, Hungria, V., additional, Leleu, X., additional, Cook, G., additional, Vela-Ojeda, J., additional, Puig, N., additional, Armour, M., additional, Stull, D.M., additional, Demers, B., additional, Romanus, D., additional, Skacel, T., additional, Ren, K., additional, and Boccadoro, M., additional

Published
2019
Full Text
View/download PDF

18. KEYNOTE-185: A randomized, open-label phase 3 study of pembrolizumab in combination with lenalidomide and low-dose dexamethasone in newly diagnosed and treatment-naive multiple myeloma (MM)

Author

Lonial, S., primary, Ribeiro de Oliveira, M., additional, Yimer, H., additional, Mateos, M.V., additional, Rifkin, R., additional, Schjesvold, F., additional, San-Miguel, J., additional, Ghori, R., additional, Marinello, P., additional, and Jagannath, S., additional

Published
2016
Full Text
View/download PDF

20. Interim Analysis of the MMRF CoMMpass Study: Comprehensive Characterization of Multiple Myeloma Patients at Diagnosis Reveals Distinct Molecular Subtypes and Clinical Outcomes

Author

Keats, J., primary, Speyer, G., additional, Christofferson, A., additional, Stephenson, K., additional, Kurdoglu, A., additional, Russell, M., additional, Aldrich, J., additional, Legendre, C., additional, Cuyugan, L., additional, Adkins, J., additional, McDonald, J., additional, Helland, A., additional, Blanski, A., additional, Hodges, M., additional, Rohrer, D., additional, Jagannath, S., additional, Siegel, D., additional, Vij, R., additional, Orloff, G., additional, Zimmerman, T., additional, Niesvizky, R., additional, Liles, D., additional, Fay, J., additional, Wolf, J., additional, Rifkin, R., additional, Derome, M., additional, Auclair, D., additional, Liang, W., additional, Kim, S., additional, Gutierrez, N., additional, Kidd, P., additional, Jewell, S., additional, Craig, D., additional, Carpten, J., additional, and Lonial, S., additional

Published
2015
Full Text
View/download PDF

22. b

Author

Poggio, T, Mukherjee, S, Rifkin, R, Raklin, A, and Verri, Alessandro

Published
2002

28. A247 Bortezomib, Dexamethasone, Cyclophosphamide, Lenalidomide (VDCR) Has High Efficacy in First-Line MM

Author

Kumar, S, primary, Flinn, Ian, additional, Noga, S, additional, Hari, R, additional, Rifkin, R, additional, Callander, N, additional, Bhandari, M, additional, Wolf, J, additional, Gasparetto, C, additional, Krishnan, A, additional, Grosman, D, additional, Glass, J, additional, Sahovic, EA, additional, Shi, J, additional, Webb, I, additional, Richardson, PG, additional, and Rajkumar, SV, additional

Published
2009
Full Text
View/download PDF

29. 79: Pegfilgrastim (P) Appears to be Equivalent to Multiple Daily Doses of Filgrastim (F) to Treat Neutropenia Post-Autologous Peripheral Blood Stem Cell Transplant (PBSCT) in Patients with Non-Hodgkin's Lymphoma: Results of a Randomized Phase II Trial

Author

Rifkin, R., primary, Beveridge, R., additional, Spitzer, G., additional, Orloff, G., additional, Mandanas, R., additional, McGaughey, D., additional, Zhan, F., additional, Boehm, K., additional, and Asmar, L., additional

Published
2008
Full Text
View/download PDF

30. Comparison of Narrowband Adaptive Filter Technologies for GPS

Author

MITRE CORP BEDFORD MA, Rifkin, R., Vaccaro, J. J., MITRE CORP BEDFORD MA, Rifkin, R., and Vaccaro, J. J.

Abstract

Narrowband interference can seriously degrade the performance of GPS systems. Several techniques exist for reducing this interference, including adaptive transversal filters, overlapped FFTs, and filter banks. All these techniques attempt to filter out the interference before the GPS receiver performs correlation. This paper compares these three interference suppression techniques for application to GPS. Likely VLSI-based designs with various levels of complexity (i.e., operation counts) for each technique are proposed and described. The effects of these designs as pre-processors on GPS ranging performance is then compared using computer simulation.

Published
2000

31. Measured Effects of a Narrowband Interference Suppressor on GPS Receivers

Author

MITRE CORP BEDFORD MA, Capozza, P. T., Holland, B. J., Hopkinson, T. M., Li, C., Moulin, D., Pacheco, P., Rifkin, R., MITRE CORP BEDFORD MA, Capozza, P. T., Holland, B. J., Hopkinson, T. M., Li, C., Moulin, D., Pacheco, P., and Rifkin, R.

Abstract

The original document contains color images.

Published
1999

32. The Static Stochastic Ground Holding Problem with Aggregate Demands

Author

Ball, Michael O., Ball, Michael O., ISR, NEXTOR, Hoffman, Robert L., Odoni, A., Rifkin, R., Ball, Michael O., Ball, Michael O., ISR, NEXTOR, Hoffman, Robert L., Odoni, A., and Rifkin, R.

Abstract

The ground delay program is a mechanism used to decrease the rate of incoming flights into an airport when it is projected that arrival demand into the airport will exceed capacity. In this paper, we present an integer programming model for plannning ground delay programs. The model considers a stochastic capacity profile which is represented by a set of airport capacity scenarios and their probabilities. Both the demand on the airport and the output of the model are represented at an aggregate level in terms of number of flights per unit time. This allows the model to be used in conjunction with arbitrarily complex preprocesses for allocating individual flights to slots. It was specifically designed to be used in the Collaborative Decision Making setting where individual flight assignments result from an iterative process involving both the airlines and traffic flow managers. We show that the linear programming dual of the model can be transformed into a network flow problem. This implies that the integer program can be solved efficiently using linear programming or network flow models.

Published
1999

41. The average roughness and fractal dimension of articular cartilage during drying.

Author

Smyth, P. A., Rifkin, R., Jackson, R. L., and Hanson, R. R.

Subjects
*FRACTAL dimensions, *ARTICULAR cartilage, *SYNOVIAL fluid, *DEHYDRATION, *SCANNING electron microscopy, *STANDARD deviations
Abstract

Cartilage is a unique material in part because of it biphasic properties. The structure of cartilage is a porous matrix of collagen fibers, permeated with synovial fluid which creates a gliding and near frictionless motion in articulating joints. However, during in vitro testing or surgery, there exists potential for cartilage to dehydrate, or dry out. The effects of this drying can influence experimental results. It is likely that drying also changes joint performance in vivo. In in vitro testing of equine cartilage explants exposed to open air, the average roughness of cartilage changes from 1.85 ± 0.78 to 3.66 ± 1.41 µm SD in a 5-h period. Significant changes in roughness in individual samples are seen within 10 min of exposure to open air. However, the multi-scale nature of cartilage, characterized by the fractal dimension, does not significantly change during the same period. The current study attempts to quantify the magnitude of error that is introduced when cartilage is removed from its native environment. SCANNING 36:368-375, 2014. © 2013 Wiley Periodicals, Inc. [ABSTRACT FROM AUTHOR]

Published
2014
Full Text
View/download PDF

48. Inhibitory Effect of Inositol Phosphates on Parathyroid Hormone-induced Bone Resorption in Organ Cultures.

Author

GOMES, B. C., KAUFMAN, H. W., BLOOM, J. R., NAVON, J., WILKENS, T. J., and RIFKIN, R. A.

Subjects
BONE resorption, PHYTIC acid, PARATHYROID hormone, INOSITOL phosphates, LABORATORY rats, METABOLIC bone disorders
Abstract

This study investigates the ability of phytic acid, its inositol phosphate derivatives (inositol penta-, tetra-, tri-, di-, and monophosphate), and inorganic phosphate to inhibit parathyroid hormone (PTH)-induced resorption of fetal rat long bones in organ culture. Pregnant rats injected with 45Ca on the 18th day of gestation were killed the next day and their fetuses removed. Half of each pair of dissected long bones was incubated in a chemically defined control medium, while the contralateral half was incubated in medium containing PTH or PTH plus the phosphate compound to be tested. 45Ca released into the medium was indicative of the amount of bone resorption. All phosphate compounds tested inhibited resorption. The inositol phosphates should be studied further to assess their suitability as therapeutic agents for treatment of metabolic bone diseases involving increased turnover. [ABSTRACT FROM AUTHOR]

Published
1984
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results